We have read with great interest the article by Ali et al regarding the delay in Onabotulinumtoxin (OBT) during the COVID-19 pandemic in three patients published in Headache (1). During the pandemic, Headache units have had to adapt by replacing face-to-face care with phone calls or visits using electronic means. Unfortunately, in many cases this has led to deterioration in patient treatment (2). As discussed in the article by Ali et al, many patients understand the situation, but as spread of COVID-19 and the associated lockdown extend over time, their viewpoint is prone to shift (1).